Zydus settles patent litigation related to seizure drug with US-based firm

Zydus Cadila has settled a patent litigation related to the US-based Supernus Pharmaceuticals’ Trokendi XR (extended-release topiramate) capsules. “Cadila Healthcare Limited and its subsidiary Zydus Pharmaceutical (USA) Inc have finalised an agreement Supernus Pharmaceuticals to settle all outstanding patent litigation related to Trokendi XR (extended-release topiramate) capsules,” said Zydus in a press release.

Two sides were involved in a patent litigation regarding Zydus’ abbreviated new drug application (ANDA) seeking approval to market generic versions of Supernus' Trokendi XR capsules.

The settlement agreement permits Zydus to begin selling a generic version of Trokendi XR on January 1, 2023, or earlier under certain circumstances.